- Home
- LAUR vs AAPG Comparison
LAUR vs AAPG Comparison
Compare LAUR & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAUR
- AAPG
- Stock Information
- Founded
- LAUR 1989
- AAPG 2009
- Country
- LAUR United States
- AAPG China
- Employees
- LAUR 31800
- AAPG N/A
- Industry
- LAUR Other Consumer Services
- AAPG Biotechnology: Pharmaceutical Preparations
- Sector
- LAUR Real Estate
- AAPG Health Care
- Exchange
- LAUR Nasdaq
- AAPG Nasdaq
- Market Cap
- LAUR 4.3B
- AAPG 3.6B
- IPO Year
- LAUR 2017
- AAPG 2025
- Fundamental
- Price
- LAUR $29.41
- AAPG $40.23
- Analyst Decision
- LAUR Strong Buy
- AAPG Buy
- Analyst Count
- LAUR 2
- AAPG 1
- Target Price
- LAUR $29.50
- AAPG N/A
- AVG Volume (30 Days)
- LAUR 1.3M
- AAPG 8.3K
- Earning Date
- LAUR 10-30-2025
- AAPG 11-06-2025
- Dividend Yield
- LAUR N/A
- AAPG N/A
- EPS Growth
- LAUR 35.40
- AAPG N/A
- EPS
- LAUR 1.68
- AAPG N/A
- Revenue
- LAUR $1,552,343,000.00
- AAPG $54,524,554.00
- Revenue This Year
- LAUR $5.64
- AAPG N/A
- Revenue Next Year
- LAUR $8.10
- AAPG $368.64
- P/E Ratio
- LAUR $17.35
- AAPG N/A
- Revenue Growth
- LAUR 0.44
- AAPG N/A
- 52 Week Low
- LAUR $15.15
- AAPG $16.50
- 52 Week High
- LAUR $31.74
- AAPG $48.45
- Technical
- Relative Strength Index (RSI)
- LAUR 50.75
- AAPG N/A
- Support Level
- LAUR $28.91
- AAPG N/A
- Resistance Level
- LAUR $30.00
- AAPG N/A
- Average True Range (ATR)
- LAUR 0.72
- AAPG 0.00
- MACD
- LAUR -0.35
- AAPG 0.00
- Stochastic Oscillator
- LAUR 12.90
- AAPG 0.00
About LAUR Laureate Education Inc.
Laureate Education Inc is an international community of universities. The company provides higher education programs and services to students through an international network of licensed universities and higher education institutions. Its geographical segments include Peru and Mexico.
About AAPG Ascentage Pharma Group International American Depository Shares
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.